Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

NCT ID: NCT05540275

Last Updated: 2023-10-06

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-05
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab with or without PTEN or TERT gene mutations.

Conditions

Recurrent Glioblastoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Patients with bevacizumab-refractory recurrent glioma with PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.

Group Type: EXPERIMENTAL

Tislelizumab plus Bevacizumab

Intervention Type: DRUG

200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks

Cohort 2

Patients with bevacizumab-refractory recurrent glioma without PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.

Group Type: EXPERIMENTAL

Tislelizumab plus Bevacizumab

Intervention Type: DRUG

200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks

Interventions

Tislelizumab plus Bevacizumab

200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent and HIPAA authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations

2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of thestudy, including disease assessment by MRI and tumor in situ fluid (TISF) collection

3. Histologically confirmed diagnosis of glioma

4. Resection surgery done at the study center (Henan Provincial People'sHospital), with an reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection

5. An interval of > 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping

6. Karnofsky performance status (KPS) of 70 or higher

7. Life expectancy > 12 weeks

Exclusion Criteria

1. More than two recurrences of GBM

2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord

3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results

4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone equivalent are permitted in absence of active autoimmune disease

5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy

6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization

7. Previous bevacizumab or other VEGF or anti-angiogenic treatment

8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy

9. Evidence of > Grade 1 CNS hemorrhage on the baseline MRI scan

10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and /or diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment

11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)

12. Prior history of gastrointestinal diverticulitis, perforation, or abscess

13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment

14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment

15. History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization

16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)

17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed

18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study

19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)

20. History of intracranial abscess within 6 months prior to randomization

21. History of active gastrointestinal bleeding within 6 months prior to randomization

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Henan Provincial People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xingyao Bu, MD, PhD

Role: STUDY_DIRECTOR

Henan Provincial People's Hospita

Locations

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Countries

China

Central Contacts

Xingyao Bu, MD, PhD

Role: CONTACT

xingyaob@zzu.edu.cn

+86037165580295

Facility Contacts

Xingyao Bu

Role: primary

xingyaob@zzu.edu.cn

References

Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, Gao Y, Mei J, Yan Z, Zhao R, Wang M, Li T, Bu X. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Cancer Immunol Immunother. 2024 Aug 6;73(10):193. doi: 10.1007/s00262-024-03774-7.

Reference Type: DERIVED

PMID: 39105794 (View on PubMed)

Other Identifiers

HenanPPH-Recurrent GBM

Identifier Type: -

Identifier Source: org_study_id